Enorama Pharma AB (publ) (STO:ERMA)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.4900
-0.0200 (-3.92%)
Mar 25, 2026, 4:45 PM CET

Enorama Pharma AB Balance Sheet

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
3.042.096.154.1412.2
Cash & Short-Term Investments
3.042.096.154.1412.2
Cash Growth
45.66%-66.11%48.66%-66.07%157.71%
Accounts Receivable
1.720.210.021.957.06
Other Receivables
0.581.22.032.371.45
Receivables
2.31.412.054.328.5
Inventory
1.7511.284.292.841.24
Prepaid Expenses
0.920.390.470.450.47
Other Current Assets
-0----
Total Current Assets
815.1612.9611.7522.41
Property, Plant & Equipment
0.010.140.861.542.22
Long-Term Deferred Charges
0.250.5920.5623.4326.3
Other Long-Term Assets
-0--12-
Total Assets
8.2615.8934.3948.7250.93
Accounts Payable
6.51.173.725.352.18
Accrued Expenses
3.371.54.022.042.24
Current Portion of Long-Term Debt
--0.131.462.09
Current Income Taxes Payable
--0.290.430.39
Other Current Liabilities
21.855.432.063.144.79
Total Current Liabilities
31.718.0910.2212.4311.68
Long-Term Debt
--0.30.451.7
Other Long-Term Liabilities
--4.334.3316.2
Total Liabilities
31.718.0914.8517.229.58
Common Stock
11.669.456.391.461.2
Additional Paid-In Capital
270.15237.99205.32176.55126.45
Retained Earnings
-305.25-239.64-192.18-149.07-106.29
Comprehensive Income & Other
---2.58-
Shareholders' Equity
-23.457.819.5431.5221.35
Total Liabilities & Equity
8.2615.8934.3948.7250.93
Total Debt
--0.441.913.79
Net Cash (Debt)
3.042.095.722.238.41
Net Cash Growth
45.66%-63.53%156.37%-73.49%-
Net Cash Per Share
-0.040.210.281.36
Filing Date Shares Outstanding
-60.4740.9325.867.69
Total Common Shares Outstanding
-60.4740.939.357.69
Working Capital
-23.727.072.75-0.6710.73
Book Value Per Share
-0.130.483.372.78
Tangible Book Value
-23.457.819.5431.5221.35
Tangible Book Value Per Share
-0.130.483.372.78
Machinery
-2.153.373.373.37
Source: S&P Global Market Intelligence. Standard template. Financial Sources.